Adverum Biotechnologies (ADVM) Misses Q3 EPS by 130c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Adverum Biotechnologies (ADVM) PT Lowered to $10 at RBC Capital
November 5, 2024 6:57 AM ESTRBC Capital analyst Luca Issi lowered the price target on Adverum Biotechnologies (NASDAQ: ADVM) to $10.00 (from $12.00) while maintaining a Sector Perform rating.
The analyst comments "ADVM reported 3Q24 results and updated timelines for the next LUNA readout (52-week results now anticipated... More
